Aged 18 years or older, male or female.
Systolic heart failure with New York Heart Association (NYHA) class II-III.
Left ventricular ejection fraction (LVEF) less than 40% by echocardiography during screening and randomization.
SCH (TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range).
Having received standard HF therapy for at least 2 weeks, having reached target dose or max tolerable dose.
Provided informed consent.

NCT03096613_inc_T1
Value
18 years or older
NCT03096613_inc_T2
Person
Aged
NCT03096613_inc_T3
Person
male
NCT03096613_inc_T4
Person
female
NCT03096613_inc_T5
Condition
Systolic heart failure
NCT03096613_inc_T6
Measurement
New York Heart Association (NYHA)
NCT03096613_inc_T7
Value
class II-III
NCT03096613_inc_T8
Measurement
Left ventricular ejection fraction (LVEF)
NCT03096613_inc_T9
Value
less than 40%
NCT03096613_inc_T10
Procedure
echocardiography
NCT03096613_inc_T11
Temporal
during screening and randomization
NCT03096613_inc_T12
Condition
SCH
NCT03096613_inc_T13
Measurement
TSH
NCT03096613_inc_T14
Value
upper limits of normal (ULN) -10mIU/L
NCT03096613_inc_T15
Measurement
FT4 level
NCT03096613_inc_T16
Value
within reference range
NCT03096613_inc_T17
Scope
TSH: upper limits of normal (ULN) -10mIU/L, and FT4 level within reference range
NCT03096613_inc_T18
Procedure
standard HF therapy
NCT03096613_inc_T19
Temporal
for at least 2 weeks
NCT03096613_inc_T20
Multiplier
target dose
NCT03096613_inc_T21
Multiplier
max tolerable dose
NCT03096613_inc_T22
Scope
target dose or max tolerable dose